PDF(Pubmed)
Abstract：
The hypothalamic neuroendocrine catecholamine dopamine regulates the lactotroph function, including prolactin (PRL) secretion, proliferation, and apoptosis. The treatment of PRL-secreting tumors, formerly known as prolactinomas, has relied mainly on this physiological characteristic, making dopamine agonists the first therapeutic alternative. Nevertheless, the group of patients that do not respond to this treatment has few therapeutical options. Prolactin is another physiological regulator of lactotroph function, acting as an autocrine/paracrine factor that controls PRL secretion and cellular turnover, inducing apoptosis and decreasing proliferation. Furthermore, the signaling pathways related to these effects, mainly JAK/STAT and PI3K/Akt, and MAPK, have been extensively studied in prolactinomas and other tumors as therapeutic targets. In the present work, the relationship between PRL pathophysiology and prolactinoma development is explored, aiming to comprehend the value of PRL and PRLR-associated pathways as exploratory fields alternative to dopamine-related approaches, which are worth physiological characteristics that might be impaired and can be potentially restored or upregulated to provide more options to the patients.
摘要：
下丘脑神经内分泌儿茶酚胺多巴胺调节催乳功能，包括催乳素（PRL）分泌，扩散,和凋亡。分泌PRL的肿瘤的治疗，以前被称为催乳素瘤，主要依靠这种生理特征，使多巴胺激动剂成为第一种治疗方法。然而，对这种治疗没有反应的患者组几乎没有治疗选择.催乳素是乳营养功能的另一种生理调节剂，作为控制PRL分泌和细胞更新的自分泌/旁分泌因子，诱导细胞凋亡和减少增殖。此外，与这些效应相关的信号通路，主要是JAK/STAT和PI3K/Akt，和MAPK，已经在泌乳素瘤和其他肿瘤中作为治疗靶标进行了广泛的研究。在目前的工作中,探讨了PRL病理生理学与泌乳素瘤发展的关系，旨在理解PRL和PRLR相关途径作为替代多巴胺相关方法的探索性领域的价值，这是值得的生理特征，可能会受损，并可以潜在地恢复或上调，为患者提供更多的选择。
